Winifred Koehler
Women's Health · Elmendorf Afb, AKNPI 1629069398
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $12,677 of the $13,397 with a category attached, or 94.6%. Organon accounts for 94.7% of it on its own, with 12 other manufacturers making up the rest. Reporting peaked in 2023 at $7,554 and has fallen 83.5% since, to $1,246 in 2025.
Across 50 payments — averaging $267.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Organon$13K
- AbbVie$192
- Astellas Pharma US Inc$164
- Novo Nordisk$126
- Sage Therapeutics, LLC$59
- Amgen$33
- plus $144 from 7 others
What the payments were for
- Speaking & faculty fees$12,67795%
- Food & beverage$6365%
- Education$851%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Organon | 17 | $12,681 |
| AbbVie | 16 | $192 |
| Astellas Pharma US Inc | 4 | $164 |
| Novo Nordisk | 2 | $126 |
| Sage Therapeutics, LLC | 2 | $59 |
| Amgen | 2 | $33 |
| Bayer | 1 | $28 |
| Supernus Pharmaceuticals, Inc. | 1 | $25 |
| Hologic Sales And Service, LLC | 1 | $22 |
| Sumitomo Pharma America, Inc. | 1 | $22 |
| IBSA Pharma Inc. | 1 | $17 |
| TMS Neurohealth Centers Inc. | 1 | $16 |
| Pfizer | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NEXPLANON$12,624
How this compares
Too few women's health providers in Alaskato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Estradiol | 17 | $1,355 |
Paid to pharmacies, not to this prescriber.
Other women's health in Elmendorf Afb
- Amanda WhollyAnchorage$4K
- Lydia MayWasilla$2K
- Leeanne MercierAnchorage$1K
- Jolene CampbellAnchorage$1K
- Rhianne ChristophersonAnchorage$335
- Haley GomezAnchorage$293
- Claire LewisBethel$270
- Elizabeth BowmanNome$124
- Ann GlasheenBethel$103
- Elisabeth JonesWasilla$96
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.